ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY - AN OVERVIEW

In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment until finally disease progression or maybe the participants are not able to tolerate the study drugs.Ubiquitin-similar proteins that control The steadiness of important super enhancer